Rather than focusing on isolated molecular targets to develop new drugs, a growing California R&D company is helping a noteworthy lineup of Big Pharma clients identify therapeutic targets by tracking biochemical processes that cause disease.
KineMed Inc. is currently raising $5 million in equity, debt and other securities, as disclosed in a regulatory filing last week.
The company’s technology is used in drug discovery and development to examine certain metabolic pathways associated with disease or health in order to provide information on disease activity and drug effects. For the in vivo platform to be used, humans or animals ingest a compound that contains nonradioactive isotopes that make their way into target molecules along a disease pathway. Fluids or tissues of interest are then isolated and analyzed for the appearance and disappearance of certain proteins using high-end mass spectroscopic techniques.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
That information is used to help drug company customers predict the efficacy and toxicity of drugs. The 11-year-old company has amassed several Big Pharma clients including Roche, Pfizer, Bayer, Merck and Bristol-Myers Squibb.
With healthcare R&D spending expected to rise next year, the company and others in the $41 billion drug development technology space could be poised for growth. KineMed’s media representative could not be reached to for additional information regarding how it will use the funding.
The Emeryville, California company also develops its own pipeline of drugs for out-licensing in areas including neurodegenerative, cardiovascular and metabolic diseases.
